Evidence map›Paper›PMID 40923906›Full record

ArticleCancer immunology research2025

Targeting LxCxE Cleft Pocket of Retinoblastoma Protein in Immunosuppressive Macrophages Inhibits Ovarian Cancer Progression.

Evgenii N Tcyganov, Taekyoung Kwak, Xue Yang, Adi Narayana Reddy Poli, Colin Hart, Avishek Bhuniya, Joel Cassel, Andrew V Kossenkov, Noam Auslander, Lily Lu and 17 more

Abstract read
In one paragraph

Article in Cancer immunology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Evgenii N Tcyganov *The Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0001-8605-7291
Taekyoung Kwak *The Wistar Institute, Philadelphia, Pennsylvania.ORCID 0009-0007-3622-8305
Xue Yang *The Wistar Institute, Philadelphia, Pennsylvania.ORCID 0009-0007-6657-6474
Adi Narayana Reddy PoliThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0001-6288-9229
Colin HartThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0009-0004-1716-5765
Avishek BhuniyaThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0001-6253-0400
Joel CasselThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0001-8465-8739
Andrew V KossenkovThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0002-1536-0418
Noam AuslanderThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0002-2037-1517
Lily LuThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0009-0003-9232-5928
Paridhima SharmaThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0009-0004-8093-1063
Maria De Grecia Cauti MendozaThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0003-1982-2592
Dmitry ZhigarevThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0002-8227-3875
Gwendolyn M CramerThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0002-1141-3391
Mark Gregory CadungogDivision of Gynecologic Oncology, Helen F. Graham Center, Christiana Care Health System, Wilmington, Delaware.ORCID 0009-0008-6027-2872
Stephanie JeanDivision of Gynecologic Oncology, Helen F. Graham Center, Christiana Care Health System, Wilmington, Delaware.ORCID 0009-0006-1501-6744
Sudeshna Chatterjee-PaerDivision of Gynecologic Oncology, Helen F. Graham Center, Christiana Care Health System, Wilmington, Delaware.ORCID 0009-0004-0928-0958
David B WeinerThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0002-2232-8512
Laxminarasimha DonthireddyThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0003-0457-8486
Bryan BristowDivision of Gynecologic Oncology, Helen F. Graham Center, Christiana Care Health System, Wilmington, Delaware.ORCID 0009-0001-8625-1980
Rugang ZhangThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0002-7255-2360
Vladimir A TyurinDepartment of Environmental Health, Center for Free Radical and Antioxidant Health, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0002-3474-1697
Yulia Y TyurinaDepartment of Environmental Health, Center for Free Radical and Antioxidant Health, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0003-0287-2091
Hülya BayirDivision of Critical Care and Hospital Medicine, Department of Pediatrics, Redox Health Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York.ORCID 0000-0003-2361-4120
Valerian E KaganDepartment of Environmental Health, Center for Free Radical and Antioxidant Health, University of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0002-7245-1885
Joseph M SalvinoThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0002-2184-5980
Luis J MontanerThe Wistar Institute, Philadelphia, Pennsylvania.ORCID 0000-0001-5799-6759

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Aaron Robert Goldman · 1985 to 2026
$75.9M
Lipids and Myeloid Cell Function in CancerR01CA165065 · NCI · WISTAR INSTITUTE · PI KAGAN, VALERIAN E, MONTANER, LUIS J · 2012 to 2022
$3.8M
National Institutes of Health (NIH) CA010815National Institutes of Health (NIH) CA1665065NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA165065Ovarian Cancer Research Alliance (OCRA) 596552Pennsylvania Department of Health (PA DOH) Cure fundsPhiladelphia Foundation (PF) Robert I Jacobs FundU.S. Department of Defense (DOD) W81XWH-19-1-0092
6 · The paper itself

Abstract

Ovarian cancer remains a major health threat with limited treatment options available. It is characterized by an immunosuppressive tumor microenvironment (TME) maintained by tumor-associated macrophages (TAM), hindering antitumor responses and immunotherapy efficacy. In this study, we showed that targeting retinoblastoma protein (Rb) by disruption of its LxCxE cleft pocket caused preferential cell death in Rbhigh M2-polarized or M2-like Rbhigh immunosuppressive TAMs by induction of endoplasmic reticulum stress, p53, and mitochondria-related cell death pathways. A reduction of protumor immunosuppressive macrophages from TME in vivo resulted in enhanced T-cell infiltration and T-cell antitumor response and inhibited cancer progression. We demonstrated increased Rb expression in TAMs in women with ovarian cancer, which was associated with poorer prognosis. Ex vivo, we showed analogous cell death induction by therapeutic Rb targeting in TAMs in post-surgery ascites from patients with ovarian cancer. Overall, our data identify the therapeutic targeting of the Rb LxCxE cleft pocket as a promising approach for ovarian cancer treatment through depletion of immunosuppressive Rbhigh TAMs and re-shaping of the TME immune landscape.

Indexed as

MacrophagesOvarian NeoplasmsRetinoblastoma ProteinTumor-Associated MacrophagesAnimalsCell Line, TumorDisease ProgressionFemaleHumansMiceTumor MicroenvironmentRetinoblastoma Protein

Identifiers

PMID40923906
PMCPMC12532034

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.